137 related articles for article (PubMed ID: 27451500)
41. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D
Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948
[TBL] [Abstract][Full Text] [Related]
42. (+)-Camphor and (-)-borneol derivatives as potential anti-orthopoxvirus agents.
Sokolova AS; Kovaleva KS; Yarovaya OI; Bormotov NI; Shishkina LN; Serova OA; Sergeev AA; Agafonov AP; Maksuytov RA; Salakhutdinov NF
Arch Pharm (Weinheim); 2021 Jun; 354(6):e2100038. PubMed ID: 33605479
[TBL] [Abstract][Full Text] [Related]
43. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens.
Sakhatskyy P; Wang S; Zhang C; Chou TH; Kishko M; Lu S
Virology; 2008 Feb; 371(1):98-107. PubMed ID: 17950773
[TBL] [Abstract][Full Text] [Related]
44. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
Quenelle DC; Prichard MN; Keith KA; Hruby DE; Jordan R; Painter GR; Robertson A; Kern ER
Antimicrob Agents Chemother; 2007 Nov; 51(11):4118-24. PubMed ID: 17724153
[TBL] [Abstract][Full Text] [Related]
45. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.
Reeves PM; Smith SK; Olson VA; Thorne SH; Bornmann W; Damon IK; Kalman D
J Virol; 2011 Jan; 85(1):21-31. PubMed ID: 20962097
[TBL] [Abstract][Full Text] [Related]
46. Rabbitpox in New Zealand White Rabbits: A Therapeutic Model for Evaluation of Poxvirus Medical Countermeasures Under the FDA Animal Rule.
Perry MR; Warren R; Merchlinsky M; Houchens C; Rogers JV
Front Cell Infect Microbiol; 2018; 8():356. PubMed ID: 30345258
[TBL] [Abstract][Full Text] [Related]
47. Smallpox eradication: destruction of variola virus stocks.
Wkly Epidemiol Rec; 2002 Feb; 77(5):34-8. PubMed ID: 11840681
[No Abstract] [Full Text] [Related]
48. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.
Zaitseva M; McCullough KT; Cruz S; Thomas A; Diaz CG; Keilholz L; Grossi IM; Trost LC; Golding H
J Virol; 2015 Mar; 89(6):3295-307. PubMed ID: 25589648
[TBL] [Abstract][Full Text] [Related]
49. The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection.
Traboulsi H; Cloutier A; Boyapelly K; Bonin MA; Marsault É; Cantin AM; Richter MV
Antimicrob Agents Chemother; 2015 Oct; 59(10):6317-27. PubMed ID: 26248373
[TBL] [Abstract][Full Text] [Related]
50. An update on the development of drugs against smallpox.
Tse-Dinh YC
Curr Opin Investig Drugs; 2008 Aug; 9(8):865-70. PubMed ID: 18666034
[TBL] [Abstract][Full Text] [Related]
51. Using the Ground Squirrel (Marmota bobak) as an Animal Model to Assess Monkeypox Drug Efficacy.
Sergeev AA; Kabanov AS; Bulychev LE; Sergeev AA; Pyankov OV; Bodnev SA; Galahova DO; Zamedyanskaya AS; Titova KA; Glotova TI; Taranov OS; Omigov VV; Shishkina LN; Agafonov AP; Sergeev AN
Transbound Emerg Dis; 2017 Feb; 64(1):226-236. PubMed ID: 25944444
[TBL] [Abstract][Full Text] [Related]
52. Preliminary study of Yinhuapinggan granule against H1N1 influenza virus infection in mice through inhibition of apoptosis.
Du HX; Zhou HF; Yang JH; Lu YY; He Y; Wan HT
Pharm Biol; 2020 Dec; 58(1):979-991. PubMed ID: 32962483
[TBL] [Abstract][Full Text] [Related]
53. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures.
Duraffour S; Snoeck R; de Vos R; van Den Oord JJ; Crance JM; Garin D; Hruby DE; Jordan R; De Clercq E; Andrei G
Antivir Ther; 2007; 12(8):1205-16. PubMed ID: 18240860
[TBL] [Abstract][Full Text] [Related]
54. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.
Berhanu A; Prigge JT; Silvera PM; Honeychurch KM; Hruby DE; Grosenbach DW
Antimicrob Agents Chemother; 2015 Jul; 59(7):4296-300. PubMed ID: 25896687
[TBL] [Abstract][Full Text] [Related]
55. Host-based antipoxvirus therapeutic strategies: turning the tables.
Fauci AS; Challberg MD
J Clin Invest; 2005 Feb; 115(2):231-3. PubMed ID: 15690079
[TBL] [Abstract][Full Text] [Related]
56. Increased susceptibility of Cantagalo virus to the antiviral effect of ST-246®.
Santos-Fernandes É; Beltrame CO; Byrd CM; Cardwell KB; Schnellrath LC; Medaglia ML; Hruby DE; Jordan R; Damaso CR
Antiviral Res; 2013 Mar; 97(3):301-11. PubMed ID: 23257396
[TBL] [Abstract][Full Text] [Related]
57. Variola virus genome sequenced from an eighteenth-century museum specimen supports the recent origin of smallpox.
Ferrari G; Neukamm J; Baalsrud HT; Breidenstein AM; Ravinet M; Phillips C; Rühli F; Bouwman A; Schuenemann VJ
Philos Trans R Soc Lond B Biol Sci; 2020 Nov; 375(1812):20190572. PubMed ID: 33012235
[TBL] [Abstract][Full Text] [Related]
58. Bioterrorism. Blocking smallpox: a second defense.
Cohen J
Science; 2001 Oct; 294(5542):500. PubMed ID: 11641477
[No Abstract] [Full Text] [Related]
59. Sequence of pathogenic events in cynomolgus macaques infected with aerosolized monkeypox virus.
Tree JA; Hall G; Pearson G; Rayner E; Graham VA; Steeds K; Bewley KR; Hatch GJ; Dennis M; Taylor I; Roberts AD; Funnell SG; Vipond J
J Virol; 2015 Apr; 89(8):4335-44. PubMed ID: 25653439
[TBL] [Abstract][Full Text] [Related]
60. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice.
Smee DF; Bailey KW; Wong MH; Sidwell RW
Antiviral Res; 2001 Oct; 52(1):55-62. PubMed ID: 11530188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
